Zegerid is a drug owned by Salix Pharmaceuticals Inc. It is protected by 7 US drug patents filed from 2013 to 2014 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 16, 2016. Details of Zegerid's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6699885 | Substituted benzimidazole dosage forms and methods of using same |
Jul, 2016
(8 years ago) |
Expired
|
| US6645988 | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(8 years ago) |
Expired
|
| US6489346 | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(8 years ago) |
Expired
|
| US5840737 | Omeprazole solution and method for using same |
Jul, 2016
(8 years ago) |
Expired
|
| US6780882 | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(8 years ago) |
Expired
|
| US7399772 | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(8 years ago) |
Expired
|
| USRE45198 | Omeprazole solution and method for using same |
Jul, 2016
(8 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zegerid's patents.
Latest Legal Activities on Zegerid's Patents
Given below is the list of recent legal activities going on the following patents of Zegerid.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Correspondence Address Change Critical | 03 Nov, 2005 | US6780882 |
| Correspondence Address Change Critical | 28 Oct, 2005 | US6780882 |
| File Marked Found | 23 Mar, 2005 | US6780882 |
| Correspondence Address Change Critical | 11 Mar, 2005 | US6780882 |
| File Marked Lost | 04 Mar, 2005 | US6780882 |
| Correspondence Address Change Critical | 11 Nov, 2004 | US6780882 |
| Correspondence Address Change Critical | 27 Oct, 2004 | US6780882 |
| Patent Issue Date Used in PTA Calculation Critical | 24 Aug, 2004 | US6780882 |
| Recordation of Patent Grant Mailed Critical | 24 Aug, 2004 | US6780882 |
| Issue Notification Mailed Critical | 05 Aug, 2004 | US6780882 |
US patents provide insights into the exclusivity only within the United States, but Zegerid is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zegerid's family patents as well as insights into ongoing legal events on those patents.
Zegerid's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zegerid's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 16, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zegerid Generics:
There are no approved generic versions for Zegerid as of now.
How can I launch a generic of Zegerid before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Zegerid's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Zegerid's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Zegerid -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 20 mg/1100 mg and 40 mg/1100 mg | 30 Apr, 2007 | 1 | 25 May, 2010 | 16 Jul, 2016 | Eligible |
| 20mg/1680mg per packet | 13 Nov, 2007 | 1 | 19 Apr, 2013 | 16 Jul, 2016 | Deferred |
| 40 mg/1680 mg per packet | 24 Aug, 2007 | 1 | 19 Apr, 2013 | 16 Jul, 2016 | Deferred |
Alternative Brands for Zegerid
Zegerid which is used for treatment of upper gastrointestinal issues including ulcers, GERD symptoms, and maintenance of esophagitis healing., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Azurity |
| |||
| Santarus |
| |||
About Zegerid
Zegerid is a drug owned by Salix Pharmaceuticals Inc. It is used for treatment of upper gastrointestinal issues including ulcers, GERD symptoms, and maintenance of esophagitis healing. Zegerid uses Omeprazole; Sodium Bicarbonate as an active ingredient. Zegerid was launched by Salix in 2004.
Approval Date:
Zegerid was approved by FDA for market use on 15 June, 2004.
Active Ingredient:
Zegerid uses Omeprazole; Sodium Bicarbonate as the active ingredient. Check out other Drugs and Companies using Omeprazole; Sodium Bicarbonate ingredient
Treatment:
Zegerid is used for treatment of upper gastrointestinal issues including ulcers, GERD symptoms, and maintenance of esophagitis healing.
Dosage:
Zegerid is available in the following dosage forms - for suspension form for oral use, capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 40MG/PACKET;1.68GM/PACKET | FOR SUSPENSION | Discontinued | ORAL |
| 20MG;1.1GM | CAPSULE | Discontinued | ORAL |
| 40MG;1.1GM | CAPSULE | Discontinued | ORAL |
| 20MG/PACKET;1.68GM/PACKET | FOR SUSPENSION | Discontinued | ORAL |
Zegerid is a drug owned by Santarus Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 16, 2016. Details of Zegerid's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7399772 | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(8 years ago) |
Expired
|
| US6699885 | Substituted benzimidazole dosage forms and methods of using same |
Jul, 2016
(8 years ago) |
Expired
|
| US6489346 | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(8 years ago) |
Expired
|
| US6645988 | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(8 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zegerid's patents.
Latest Legal Activities on Zegerid's Patents
Given below is the list of recent legal activities going on the following patents of Zegerid.
| Activity | Date | Patent Number |
|---|---|---|
| | ||
| Correspondence Address Change Critical | 03 Nov, 2005 | US6780882 |
| Correspondence Address Change Critical | 28 Oct, 2005 | US6780882 |
| File Marked Found | 23 Mar, 2005 | US6780882 |
| Correspondence Address Change Critical | 11 Mar, 2005 | US6780882 |
| File Marked Lost | 04 Mar, 2005 | US6780882 |
| Correspondence Address Change Critical | 11 Nov, 2004 | US6780882 |
| Correspondence Address Change Critical | 27 Oct, 2004 | US6780882 |
| Patent Issue Date Used in PTA Calculation Critical | 24 Aug, 2004 | US6780882 |
| Recordation of Patent Grant Mailed Critical | 24 Aug, 2004 | US6780882 |
| Issue Notification Mailed Critical | 05 Aug, 2004 | US6780882 |
US patents provide insights into the exclusivity only within the United States, but Zegerid is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zegerid's family patents as well as insights into ongoing legal events on those patents.
Zegerid's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zegerid's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 16, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zegerid Generics:
There are no approved generic versions for Zegerid as of now.
Alternative Brands for Zegerid
Zegerid which is used for treatment of upper gastrointestinal issues including ulcers, GERD symptoms, and maintenance of esophagitis healing., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Azurity |
| |||
| Santarus |
| |||
About Zegerid
Zegerid is a drug owned by Santarus Inc. It is used for treatment of upper gastrointestinal issues including ulcers, GERD symptoms, and maintenance of esophagitis healing. Zegerid uses Magnesium Hydroxide; Omeprazole; Sodium Bicarbonate as an active ingredient. Zegerid was launched by Santarus in 2006.
Approval Date:
Zegerid was approved by FDA for market use on 24 March, 2006.
Active Ingredient:
Zegerid uses Magnesium Hydroxide; Omeprazole; Sodium Bicarbonate as the active ingredient. Check out other Drugs and Companies using Magnesium Hydroxide; Omeprazole; Sodium Bicarbonate ingredient
Treatment:
Zegerid is used for treatment of upper gastrointestinal issues including ulcers, GERD symptoms, and maintenance of esophagitis healing.
Dosage:
Zegerid is available in tablet, chewable form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 700MG;40MG;600MG | TABLET, CHEWABLE | Discontinued | ORAL |
| 700MG;20MG;600MG | TABLET, CHEWABLE | Discontinued | ORAL |